Aurinia Pharmaceuticals Inc. (AUPH)
Summary
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
Aurinia Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 725 | $9,149.66 | $11,690.62 | $2,540.96 | 27.77% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 92,149 | $1.56M | $1.46M | -$103,208.35 | -6.6% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 300 | $4,785 | $4,635 | -$150 | -3.13% |
| LN Louis Navellier NAVELLIER & ASSOCIATES Inc. | 257,142 | $3.83M | $3.82M | -$8,568.98 | -0.22% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,014 | $9,312.15 | $15,666.3 | $6,354.15 | 68.24% |
Aurinia Pharmaceuticals Inc. (AUPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aurinia Pharmaceuticals Inc. ever had a stock split?
Aurinia Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kevin C. Tang CEO | NASDAQ (NMS) Exchange | 05156V102 CUSIP |
| CA Country | 128 Employees | - Last Dividend | 23 Oct 2013 Last Split | 26 Jan 1999 IPO Date |
Overview
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company established in 1993 and based in Edmonton, Canada. The company dedicates its efforts to developing and commercializing innovative therapies intended to address diseases with significant unmet medical needs within the United States. Through its focus on specialized medication, Aurinia Pharmaceuticals has positioned itself as a key player in the healthcare industry, particularly in the realm of treatment for complex diseases. Its partnership with Otsuka Pharmaceutical Co., Ltd. underlines its commitment to expanding its reach and enhancing the impact of its therapeutic solutions on patients' lives.
Products and Services
- LUPKYNIS - This product is designed for the treatment of adult patients suffering from active lupus nephritis, a serious autoimmune disease that affects the kidneys. Aurinia Pharmaceuticals has successfully brought LUPKYNIS to the commercial stage, offering hope and a much-needed solution to individuals dealing with this challenging condition. The availability of LUPKYNIS underscores the company's focus on addressing diseases that have historically had limited treatment options.
